Melanovus Oncology Inc entered the industry of Commercial Biotechnical Research in 2012 and has grown to employ 1 to 4 people, generating an annual revenue of $100.000 to $499.999. The NAICS classifies this business under the code 541711, which describes it as a Commercial Biotechnical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Biotechnical Research. The business provides service to the B2B market.
To acquire more information, please contact Thomas Lytle by calling (717) 482-2012 during business hours. You can also write to the business’ Single Location at 1214 Research Boulevard, Hummelstown, Pennsylvania PA 17036. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
Company: | Melanovus Oncology Inc |
Representative: | Thomas Lytle |
Place of Business: | 1214 Research Boulevard, Hummelstown, PA 17036 |
Contact Number: | (717) 482-2012 |
Type of Service: | Commercial Biotechnical Research |
SIC Number: | 8731 |
NAICS Number: | 541711 |
Locality: | Single Location |
Market Type: | B2B (Business to Business) |
Began: | 2012 |
Income/Year: | $100.000 to $499.999 |
Laborers: | 1 to 4 |
Share This Company: |
Melanovus Oncology Inc is a company operating from Dauphin, Pennsylvania providing professional Commercial Biotechnical Research and relevant B2B variables. It was founded in 2012 and registered with the SIC code 8731 as Commercial Biotechnical Research, and with the NAICS code 541711 as Commercial Biotechnical Research.
With a current employee count of 1 to 4, Melanovus Oncology Inc has gone to report making $100.000 to $499.999 per annum on its journey towards growth. This company invites you to contact its representative Thomas Lytle at (717) 482-2012 for related queries, or to locate its Single Location using the coordinates 40.262648,-76.686498.
The Single Location can also be found at the street address 1214 Research Boulevard in Hummelstown, Pennsylvania 17036 and can be engaged online through the company website at , the company Twitter , and Facebook page .